Shanghai AB PharmaTech Ltd.
Quick facts
Phase 2 pipeline
- ABP1011T · Diabetes
ABP1011T is a small molecule that targets the SGLT2 receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Related
- Sector hub: All tracked pharma companies